HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea · Delayed Price · Currency is KRW 9,950.00
+60.00 (0.61%)
Oct 28, 2026, 3:30 PM KST
HLB Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
| 326,348 | 225,238 | 338,419 | 75,194 | 58,507 | 80,206 | |
Market Cap Growth | 52.30% | -33.44% | 350.06% | 28.52% | -27.05% | - |
Enterprise Value | 327,154 | 215,584 | 336,454 | 77,595 | - | - |
Last Close Price | 9890.00 | 14781.18 | 22208.63 | 5003.85 | 3893.42 | 5916.16 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
PE Ratio | 119.68 | 49.27 | 167.55 | 159.09 | - | - |
PS Ratio | 1.29 | 1.10 | 2.47 | 2.08 | 2.85 | 5.16 |
PB Ratio | 2.48 | 1.80 | 2.91 | 4.20 | 3.44 | 4.77 |
P/TBV Ratio | 2.58 | 1.86 | 3.02 | 4.31 | 3.50 | 4.83 |
P/FCF Ratio | - | - | 83.73 | - | - | - |
P/OCF Ratio | 74.95 | 395.87 | 49.47 | 55.56 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
EV/Sales Ratio | 1.29 | 1.05 | 2.45 | 2.15 | - | - |
EV/EBITDA Ratio | 56.97 | 41.65 | 51.26 | 25.19 | - | - |
EV/EBIT Ratio | 279.16 | 202.65 | 228.26 | 53.85 | - | - |
EV/FCF Ratio | - | - | 83.24 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
Debt / Equity Ratio | 0.15 | 0.17 | 0.14 | 0.74 | 0.45 | 0.89 |
Debt / EBITDA Ratio | 3.12 | 4.00 | 2.45 | 4.28 | - | - |
Debt / FCF Ratio | - | - | 3.97 | - | - | - |
Net Debt / Equity Ratio | 0.01 | -0.01 | -0.05 | -0.11 | -0.08 | 0.21 |
Net Debt / EBITDA Ratio | 0.13 | -0.28 | -0.90 | -0.64 | 0.30 | -1.27 |
Net Debt / FCF Ratio | -0.19 | 0.22 | -1.47 | 44.86 | 0.49 | -1.18 |
Asset Turnover | 1.48 | 1.25 | - | 0.88 | 0.54 | - |
Inventory Turnover | 4.65 | 3.79 | - | 3.27 | 3.13 | - |
Quick Ratio | 1.07 | 1.17 | 1.02 | 1.01 | 0.94 | 1.01 |
Current Ratio | 1.88 | 1.94 | 1.64 | 1.26 | 1.31 | 1.31 |
Return on Equity (ROE) | 2.17% | 3.79% | - | 2.71% | -41.77% | - |
Return on Assets (ROA) | 0.69% | 0.40% | - | 2.19% | -9.55% | - |
Return on Invested Capital (ROIC) | 1.22% | 0.83% | 2.33% | 9.14% | -32.41% | -18.92% |
Return on Capital Employed (ROCE) | 1.40% | 0.80% | 1.20% | 6.30% | -28.80% | -17.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
Earnings Yield | 0.84% | 2.03% | 0.60% | 0.63% | -12.07% | -6.79% |
FCF Yield | -1.32% | -2.95% | 1.19% | -0.06% | -4.91% | -3.77% |
Buyback Yield / Dilution | -2.00% | -2.25% | -130.84% | -2.30% | -13.08% | - |